Preferences help
enabled [disable] Abstract
Number of results
2019 | 9 | 1 | 22-26
Article title

Cardiac complications during DLBCL treatment using R-CHOP

Title variants
Languages of publication
Diffuse large B‐cell lymphoma (DLBCL) is the most frequent of non-Hodgkin’s lymphomas in the world. Immunochemotherapy with rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisone (R‐CHOP) is the first-line treatment in this disease. Rituximab is a chimeric murine-human monoclonal anti-CD20 antibody, which binds specifically with CD20 receptor located on majority of mature B-cell lymphocytes. We are presenting the case of sudden cardiac arrest with ventricular fibrillation after intravenous injection of rituximab in a patient with DLBCL type NGC.
Physical description
  • Department of Oncocardiology, Holy Cross Cancer Center, Kielce
  • Department of Hematology, Immunology and Bone Marrow Transplantation, Holy Cross Cancer Center, Kielce
  • Department of Hematology, Immunology and Bone Marrow Transplantation, Holy Cross Cancer Center, Kielce
  • Department of Hematology, Immunology and Bone Marrow Transplantation, Holy Cross Cancer Center, Kielce. The Faculty of Medicine and Health Sciences, The Jan Kochanowski University, Kielce
  • 1. Li S, Young KH, Mederidos LJ. Diffuse large B-cell lymphoma. Pathology 2018; 50: 74-87.
  • 2. Ziepert M, Hasenclever D, Kuhnt E et al. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20 B-Cell Lymphoma in the Rituximab Era. J Clin Oncol 2010; 28: 14.
  • 3. Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010; 9: 116.
  • 4. Martelli M, Ferreri AJM, Agostinelli C et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013; 87: 146-171.
  • 5. Seruga B, Sterling L, Wang L, Tannock IF. Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials. J Clin Oncol 2011; 29: 174-185.
  • 6. Foran JM, Rohatiner AZS, Cunningham D et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18: 317-324.
  • 7. Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-Induced Polymorphic Ventricular Tachycardia. Tex Heart Inst J 2010; 37(2): 218-220.
  • 8. Lee L, Kukreti V. Rituximab-Induced Coronary Vasospasm. Case Rep Hematol 2012. Article ID 984986. DOI:10.1155/2012/984986.
  • 9. Ke C, Khosla A, Davis MK et al. A Case of Coronary Vasospasm after Repeat Rituximab Infusion. Case Rep Cardiol 2015. Article ID 523149.
  • 10. Naqvi SY, Hanley A, Crowley J. Ventricular fibrillation due to coronary vasospasm. BMJ Case Rep 2014. DOI:10.1136/bcr-2013-203253.
  • 11. Arenja N, Zimmerli L, Urbaniak P, Vogel R. Acute anterior myocardial infarction after rituximab. Dtsch Med Wochenschr 2016; 141: 500-503. DOI: 10.1055/s-0041-106055.
  • 12. Bambury R, Gallagher F, Dodd JD, Fennelly D. Primary cardiac lymphoma: diagnostic tools and treatment challenges. Ir J Med Sci 2011; 180: 271-273. DOI: 10.1007/s11845-009-0446-x.
  • 13. Ng KH, Dearden C, Gruber P. Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears? BMJ Case Rep 2015. DOI:10.1136/bcr2014-208203.
  • 14. Arai Y, Tadokoro J, Mitani K. Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. Am J Hematol 2005; 78: 316-319.
  • 15. Janas E, Priest R, Malhotra R. Functional role of lipid rafts in CD20 activity? Biochem Soc Symp 2005; 72: 165-175.
  • 16. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005; 8: 140-174.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.